Subscribe
gil-c-shutterstock-com-4
Gil C / Shutterstock.com
23 March 2016Americas

Merck claims hepatitis C patent win

A US court has upheld the validity of two patents owned by Merck in the pharmaceutical company’s dispute with drug maker Gilead centring on hepatitis C treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Merck handed $200m in Gilead hepatitis C row
29 March 2016   Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.
Americas
Gilead v Merck hepatitis C dispute rocked by new allegation
3 May 2016   A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.
Americas
Federal Circuit affirms Merck ‘unclean hands’ verdict
26 April 2018   The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Merck handed $200m in Gilead hepatitis C row
29 March 2016   Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.
Americas
Gilead v Merck hepatitis C dispute rocked by new allegation
3 May 2016   A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.
Americas
Federal Circuit affirms Merck ‘unclean hands’ verdict
26 April 2018   The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.

More on this story

Americas
Merck handed $200m in Gilead hepatitis C row
29 March 2016   Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.
Americas
Gilead v Merck hepatitis C dispute rocked by new allegation
3 May 2016   A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.
Americas
Federal Circuit affirms Merck ‘unclean hands’ verdict
26 April 2018   The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility